Cerbios-Pharma Opens New R&D Center for High Potency APIs and mAbsBy
Cerbios-Pharma SA has opened a new research and development (R&D) center for high-potency active pharmaceutical ingredients (HPAPIs) and monoclonal antibody (mAb) development. Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide. Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for mAbs, recombinant proteins and pharma probiotics.
The construction of the investment was approved in November 2013 and started in April 2014. The new building consists of four floors of 280 square meters each. The second floor houses biological R&D, with three dedicated laboratories for the development of mAbs and/or recombinant proteins based on Chinese hamster ovary (CHO) mammalian cells and a large laboratory to develop pharmaceutical probiotics. The first floor houses a new additional GMP archive and offices for the directors and for the managers of R&D and quality assurance. The ground floor houses chemical R&D, doubling the capacity to develop HPAPIs for contract manufacturing services ,including Safebridge Category 4 products. Underground floors house two warehouses (one for R&D and one for production) and personnel services.